David Fuller
Chief Tech/Sci/R&D Officer chez DIMERIX LIMITED
Fortune : 1 759 $ au 31/03/2024
Profil
David Fuller is currently the Chairman of EpiAxis Therapeutics Pty Ltd.
He also holds the position of Non-Executive Director at AdAlta Ltd.
since 2020 and will be the Chief Medical Officer at Dimerix Ltd.
starting in 2023.
Previously, he was the Chief Medical Officer at Race Oncology Ltd.
from 2021 to 2022.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0,00% | 30/06/2023 | 1 899 ( 0,00% ) | 1 759 $ | 31/03/2024 |
Postes actifs de David Fuller
| Sociétés | Poste | Début |
|---|---|---|
| ADALTA LIMITED | Director/Board Member | 22/07/2020 |
| DIMERIX LIMITED | Chief Tech/Sci/R&D Officer | 23/10/2023 |
EpiAxis Therapeutics Pty Ltd.
 EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Chairman | - |
Anciens postes connus de David Fuller
| Sociétés | Poste | Fin |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | 11/11/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| DIMERIX LIMITED | Health Technology |
| ADALTA LIMITED | Health Technology |
| RACE ONCOLOGY LIMITED | Health Technology |
| Entreprise privées | 1 |
|---|---|
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Health Technology |
